miR-1306 Mediates the Feedback Regulation of the TGF-β/SMAD Signaling Pathway in Granulosa Cells.
Liu YangXing DuLu LiuQiuyu CaoZengxiang PanQifa LiPublished in: Cells (2019)
Transforming growth factor-β receptor II (TGFBR2), the type II receptor of the TGF-β/SMA- and MAD-related protein (SMAD) signaling pathway, plays a crucial role in TGF-β signal transduction and is regulated by multiple factors. Nevertheless, the modulation of the non-coding RNA involved in the process of TGFBR2 expression in ovaries is not well studied. In our study, we isolated and characterized the 3'-untranslated region (UTR) of the porcine TGFBR2 gene and microRNA-1306 (miR-1306) was identified as the functional miRNA that targets TGFBR2 in porcine granulosa cells (GCs). Functional analysis showed that miR-1306 promotes apoptosis of GCs as well as attenuating the TGF-β/SMAD signaling pathway targeting and impairing TGFBR2 in GCs. Moreover, we identified the miR-1306 core promoter and found three potential SMAD4-binding elements (SBEs). Luciferase and chromatin immunoprecipitation (ChIP) assays revealed that the transcription factor SMAD4 directly binds to the miR-1306 core promoter and inhibits its transcriptional activity. Furthermore, the TGF-β/SMAD signaling pathway is modulated by SMAD4 positive feedback via inhibition of miR-1306 expression in GCs. Collectively, our findings provide evidence of an epigenetic mechanism that modulates as well as mediates the feedback regulation of the classical TGF-β/SMAD signaling pathway in GCs from porcine ovaries.
Keyphrases
- transforming growth factor
- epithelial mesenchymal transition
- signaling pathway
- cell proliferation
- induced apoptosis
- long non coding rna
- pi k akt
- cell cycle arrest
- transcription factor
- long noncoding rna
- poor prognosis
- gene expression
- dna methylation
- endoplasmic reticulum stress
- high throughput
- cell death
- oxidative stress
- binding protein
- type diabetes
- adipose tissue
- polycystic ovary syndrome
- dna binding
- copy number
- insulin resistance
- risk assessment
- cancer therapy